P
MRTX

Pitcairn’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Pitcairn’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,317
Closed -$233K – 645
2021
Q3 		$233K Sell
1,317
-32
-2% -$5.15K 0.02% 581
2021
Q2 		$218K Sell
1,349
-80
-6% -$12.8K 0.01% 575
2021
Q1 		$245K Sell
1,429
-243
-15% -$48.1K 0.02% 540
2020
Q4 		$367K Sell
1,672
-397
-19% -$85.8K 0.03% 377
2020
Q3 		$344K Sell
2,069
-91
-4% -$12.5K 0.03% 330
2020
Q2 		$247K Buy
+2,160
New +$209K 0.02% 406
2020
Q1 		– Sell
-1,648
Closed -$213K – 562
2019
Q4 		$213K Buy
+1,648
New +$159K 0.02% 511

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Pitcairn's MRTX Position: Q4 2021 in Review

Pitcairn sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 1,317 shares — an estimated $233K sold.

Pitcairn first reported a position in MRTX in Q4 2019 and held it in 7 quarters. The position peaked at $367K in Q4 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

  • Pitcairn reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Pitcairn sold 1,317 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $233K.
  • Pitcairn first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
  • Pitcairn's Mirati Therapeutics, Inc. Common Stock position peaked at $367K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Pitcairn's 13F filing for Q4 2021, filed 14 Feb 2022.